Orgenesis Inc.
Orgenesis Inc. is dedicated to unlocking the potential of cell and gene therapies (CGTs) by providing affordable and accessible solutions. The company focuses on overcoming the challenges of processing personalized CGTs locally to impact patients globally. Through its POCare Platform, Orgenesis aims to lower costs and standardize high-quality CGTs, making advanced therapies more accessible to patients worldwide.
Orgenesis Inc.
What We Do
An advanced monomeric anti-CD19 Chimeric Antigen Receptor T cells (CAR-T) therapy to treat relapsed or refractory B-cell Acute Lymphoblastic Leukemia (B-ALL) patients.
An anti-cancer cellular vaccine that utilizes patient antigen presenting cells (APCs) pulsed with relevant cancer cells to target the entire repertoire of tumour cell antigens and elicit immune response against hard to treat cancers.
An adoptive cell therapy using tumor-infiltrating lymphocytes (TILs) as a personalized cancer treatment platform via infusion of autologous T lymphocytes expanded from tumors.
Ranpirnase is a ribonuclease (RNA) degrading enzyme used to target double-stranded RNA including miRNA precursors for use with external genital warts (EGW) and anal dysplasia.
A regenerative approach to transform patient’s own liver cells into fully functional and physiologically glucose-responsive AIPs designed to provide long-term insulin independence.
Provides a pathway for unlocking the full potential of cell and gene therapies (CGTs) in an affordable and accessible format.